Kalray Wins Flash Memory Summit Award for the Second Year in a Row
10.8.2023 17:48:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for the high-performance, data-centric computing and storage markets, has been recognized as the leader of the DPU category in the 17th Annual Flash Memory Summit Awards competition.
Flash Memory Summit (FMS) is the world’s largest international comprehensive memory and storage showcase, hosted at the Santa Clara Convention Center, California, USA. The new Kalray K220-LP Storage Acceleration Card, powered by Kalray's 3rd generation DPU processor, won the FMS Award in the DPU category. This Flash Memory Summit Award symbolizes the industry's acknowledgment of the innovation and business value that Kalray solutions bring to the market.
KALRAY UNVEILS ITS NEW K220-LP™ SMART STORAGE ACCELERATOR
Kalray’s K220-LP™ Smart Storage Accelerator (SSA) was introduced at FMS this year, bringing storage offload to the next level. By offloading intensive storage data services from the main CPU, the SSA releases all the potential of NVMe SSDs in any server with local NVMe devices. The main CPU is freed to perform billable tasks while all storage-related tasks are offloaded to the Kalray K220-LP™ Smart Storage Accelerator.
“Customers have a need to maximize their server investments by pursuing greater optimization and performance. This can be achieved by offloading storage data services to specialized processors for maximum ROI of the server infrastructure,” said Jay Kramer, chairman of the awards program and president of Network Storage Advisors Inc. “We are proud to recognize Kalray’s Smart Storage Accelerators for their ability to efficiently store both data and metadata on storage class memory (SCM) while offloading storage data services and applications from the main CPU. This solution enables customers to realize the full potential of local NVMe SSDs deployed in any industry-standard server.”
KALRAY DEMONSTRATES THAT QLC MEMORY ADOPTION BENEFITS DATA CENTERS
As a powerful use case, Kalray demonstrated how its solution allows a new generation of SSDs, called QLC SSDs, to be adopted into data centers without requiring any changes to the data center operating system, file system, or applications. Kalray DPUs have accelerators, fast coherent memory, and flexible programmability, which makes them ideal for storage management functions such as managing new QLC technology. Thanks to Kalray’s solution, data centers can take full advantage of the price, capacity, and performance benefits of QLC flash devices. The result is a data center that realizes the benefits of QLC without performance and durability penalties and without the need to modify existing software.
“QLC SSDs present great economic advantages by delivering greater capacity and density. But compared to other SSD types, QLC technology has challenges to overcome, including lower endurance, higher latency, and reduced performance under heavy workloads,” added Jay Kramer. “We are proud to recognize Kalray’s Smart Storage Accelerators for their highly effective performance in enabling a simple deployment on industry-standard servers. This solution allows customers to achieve cost and capacity benefits of QLC devices transparently, with no hardware architectural changes and no software stack changes.”
ACKNOWLEDGEMENT OF THE SOLUTION’S INNOVATION
“It is a great honor to win a Flash Memory Summit award for the second year in a row,” said Éric Baissus, chief executive officer of Kalray. “This award represents strong recognition of the value of our solutions. Customers who integrate our new K220-LP™ SSA into their servers can accelerate the transition from traditional storage architectures relying on SAS (Serial Attached SCSI) to high-performance, power-efficient NVMe-based solutions.”
The K220-LP™ solution includes Kalray’s AccessCore® Storage (ACS) software SDK. Thanks to ACS SDK, the K220-LP™ SSA is fully programmable, enabling offload of custom storage or computational application processing, thus removing the usual bottlenecks of traditional architectures. The Kalray solution enables data centers to leapfrog outdated technologies that are unable to sustain the storage requirements of demanding workloads and embrace the benefits of modern, scalable, and flexible data solutions with minimal effort.
This is the second consecutive award Kalray has received from Flash Memory Summit, maintaining momentum in innovation following last year’s award for most innovative technology with Flashbox™.
ABOUT KALRAY
Kalray (Euronext Growth Paris – FR0010722819 – ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures.
Kalray’s offerings include unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as leading-edge software-defined storage and data management solutions. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers and to design the best solutions in fast-growing sectors such as AI, media & entertainment, life science, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. Visit us at www.kalrayinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809063602/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Tel. 04 76 18 90 71
ACTUS finance & communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Tel. 01 53 67 36 72
PRESS
Diana EADINGTON
communication@kalrayinc.com
Tel. +44 7939 877 880
ACTUS finance & communication
Serena BONI
sboni@actus.fr
Tel. 04 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom